Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingwen Dong

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|January 9, 2007
Estimating the predictive quality of dose-response after model selectionChuanpu Hu, Yingwen Dong
Statistics in Medicine|July 28, 2020
Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer typesJin Jin, Marie-Karelle Riviere, Xiaodong Luo, et al.
Journal of Clinical Pharmacology|June 27, 2014
Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal functionPing He, Doug Kerr, Thomas Marbury, et al.
Therapeutic Innovation & Regulatory Science|June 22, 2024
Use of Seamless Study Designs in Oncology Clinical Development- A Survey Conducted by IDSWG Oncology Sub-teamYingwen Dong, Gautier Paux, Kristine Broglio, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 19, 2012
Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristicsStacy A Rudnicki, James D Berry, Evan Ingersoll, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2011
Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patientsChi-Chung Li, Peng Sun, Yingwen Dong, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 18, 2013
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trialsJames D Berry, Robert Miller, Dan H Moore, et al.
Thrombosis and Haemostasis|March 11, 2016
Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia AJohnny N Mahlangu, Margaret Ragni, Naresh Gupta, et al.
The Lancet. Neurology|September 27, 2013
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialMerit E Cudkowicz, Leonard H van den Berg, Jeremy M Shefner, et al.
Journal for Immunotherapy of Cancer|January 21, 2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter studyPaolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|January 9, 2007
Estimating the predictive quality of dose-response after model selectionChuanpu Hu, Yingwen Dong
Statistics in Medicine|July 28, 2020
Bayesian methods for the analysis of early-phase oncology basket trials with information borrowing across cancer typesJin Jin, Marie-Karelle Riviere, Xiaodong Luo, et al.
Journal of Clinical Pharmacology|June 27, 2014
Pharmacokinetics of renally excreted drug dexpramipexole in subjects with impaired renal functionPing He, Doug Kerr, Thomas Marbury, et al.
Therapeutic Innovation & Regulatory Science|June 22, 2024
Use of Seamless Study Designs in Oncology Clinical Development- A Survey Conducted by IDSWG Oncology Sub-teamYingwen Dong, Gautier Paux, Kristine Broglio, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 19, 2012
Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a Phase II study: subgroup analysis of demographic and clinical characteristicsStacy A Rudnicki, James D Berry, Evan Ingersoll, et al.
Antimicrobial Agents and Chemotherapy|February 9, 2011
Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patientsChi-Chung Li, Peng Sun, Yingwen Dong, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|January 18, 2013
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trialsJames D Berry, Robert Miller, Dan H Moore, et al.
Thrombosis and Haemostasis|March 11, 2016
Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia AJohnny N Mahlangu, Margaret Ragni, Naresh Gupta, et al.
The Lancet. Neurology|September 27, 2013
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialMerit E Cudkowicz, Leonard H van den Berg, Jeremy M Shefner, et al.
Journal for Immunotherapy of Cancer|January 21, 2022
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter studyPaolo Andrea Zucali, Chia-Chi Lin, Bradley C Carthon, et al.
Pageof 1